�Synta Pharmaceuticals Corp., (NASDAQ: SNTA) proclaimed the publishing of raw findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that describe the novel mechanism of action of elesclomol: driving programmed cell death (programmed cell death) in malignant neoplastic disease cells through the selective induction of oxidative strain. Elesclomol is currently in a world, pivotal Phase 3 clinical trial (SYMMETRYSM) in combination with paclitaxel for the treatment of metastatic melanoma.
"These results confirm that elesclomol powerfully and selectively induces programmed cell death in cancer cells by increasing the level of reactive o species (ROS) beyond sustainable levels," aforementioned James Barsoum, Ph.D., Senior Vice President, Research, Synta Pharmaceuticals. "Elevated ROS levels and susceptibility to farther increases in ROS are fundamental characteristics of cancer cells that differentiate them from normal non-cancerous cells. Exploiting this special vulnerability represents a novel approach path to selectively targeting and killing cancer the Crab cells. The findings likewise suggest that elesclomol stool substantially enhance the efficaciousness of certain other antitumour therapies when given in combination. These results collectively indicate the potential of oxidative tension induction as a new therapeutic choice for treating multiple types of cancers, either as a single agent or in combination. We are excited by the potentiality of this new mechanism category, peculiarly for difficult-to-treat cancers such as malignant melanoma that receive not been responsive to chemotherapy or other prior approaches."
Oxidative stress occurs when there is an elevated spirit level of responsive oxygen species (ROS) in cells. Superoxide, hydrogen peroxide and hydroxyl group radicals ar examples of reactive oxygen species. ROS levels commode increase in a sort of situations including exposure to bacteria or viruses, a go up in prison cell proliferation, or an addition in cubicle metabolism. Prolonged exposure to elevated levels of ROS can lead up a episode of protective events culminating in the ultimate self-protection mechanism, programmed cell decease (apoptosis). Normal, non-cancerous cells have a strong antioxidant capacity which guards against excessive levels of ROS. In dividing line, cancer cells operate at a a great deal higher storey of oxidative stress and have a greatly diminished antioxidant electrical capacity. The raised level of ROS and diminished antioxidant capacity exit cancer cells particularly vulnerable to further increases in oxidative accent.
The results of the new in vitro studies demonstrated that elesclomol causes apoptosis in cancer cells through the induction of oxidative strain. The step-up in ROS was ascertained by measurement the levels of responsive oxygen species such as hydrogen peroxide directly and by measurement the increased expression of genes that are induced by the presence of high levels of ROS. Elesclomol demonstrated potent and cancer-specific initiation of oxidative stress and apoptosis in multiple cancer cell types, including malignant melanoma, leukemias and lymphomas as well as breast, prostate, ovarian, colon, and lung. Specifically:
- Elesclomol rapidly induced the aggregation of intracellular ROS as detected by fluorescent microscopy;
- Elesclomol robustly induced the expression of many genes regulated by ROS such as high temperature shock proteins and metallothionein genes, which is a signature written text profile of cells under oxidative stress; and
- Pretreatment of cells with antioxidants blocked elesclomol-induced ROS production and programmed cell death.
"These new findings highlight the potential of oxidative stress generalisation," said Dr. Barsoum. "Cancer types that may be especially sensitive to this mechanism ar those known to have particularly high levels of oxidative tension, including, malignant melanoma, prostate, breast, ovarian, and hematologic cancers."
The on-going Phase 3 SYMMETRY test of elesclomol in metastatic melanoma is expected to have initial results in early 2009. Phase 2 studies of elesclomol in other indications are aforethought for the fourth quarter of 2008 and in 2009. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of elesclomol.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focussed on discovering, developing, and commercializing small molecule drugs to stretch out and enhance the lives of patients with severe medical conditions, including cancer and inveterate inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a various pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists victimisation our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug nominee, elesclomol, which is in a globose, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit http://www.syntapharma.com.
About Elesclomol
Elesclomol is a novel, injectable, investigational drug nominee that triggers apoptosis (programmed cell last) in cancer cells. Cancer cells operate at high levels of reactive o species, or oxidative tension. Elesclomol is believed to act by increasing the level of oxidative strain in crab cells even further, beyond sustainable levels, inducing caspase-mediated cell death. This mechanics of action, called oxidative stress inductance, represents a novel way of selectively targeting and killing genus Cancer cells.
In a double blind, randomized, controlled Phase 2b clinical test in 81 patients with stage IV metastatic melanoma, elesclomol in combination with paclitaxel met the primary endpoint, doubling the average time patients survived without their disease progressing, compared to paclitaxel alone (p = 0.035). The most common adverse events in the elesclomol asset paclitaxel grouping included fatigue, alopecia, stultification, nausea, hypoaesthesia, arthralgia, insomnia, diarrhea, and anemia.
A pivotal Phase 3 clinical trial of elesclomol in combination with paclitaxel in patients with stage IV metastatic melanoma (the SYMMETRY(SM) trial) is ongoing; Phase 2 trials in other indications, and in combination with other agents, are planned. Elesclomol has received Fast Track and Orphan Drug designation from the FDA for metastatic melanoma, and the Phase 3 SYMMETRY trial has completed a Special Protocol Assessment process with the FDA. Information around the SYMMETRY trial privy be set up at hypertext transfer protocol://www.symmetrymelanomastudy.com, or http://www.clinicaltrials.gov.
About Metastatic Melanoma
Melanoma, the most deadly form of skin cancer, arises from melanocytes, the pigment-producing cells of the peel. According to the American Cancer Society, melanoma accounts for about five pct of all skin cancers but causes about 75% of all skin cancer-related deaths. An estimated 60,000 people will be diagnosed and nearly 8,200 people will die from melanoma this year in the U.S. unequaled. If diagnosed and surgically removed patch localized in the outermost skin layer, melanoma is potentially curable; however, for patients with metastatic disease the prospect is poor, with limited available treatments and an expected survival of only six to nine months. The relative incidence of malignant melanoma has increased more rapidly than whatever other cancer during the past ten years. The FDA has not approved a novel, small speck drug for the treatment of metastatic melanoma in over 30 years.
Safe Harbor Statement
This media release whitethorn contain forward-looking statements nearly Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the enjoyment of advanced terminology such as "will", "would", "should", "", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and advancement of our clinical and preclinical programs and fiscal guidance for 2008, reflect our electric current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year terminated December 31, 2007 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, demur as requisite by practice of law.
Synta Pharmaceuticals
More info
Tuesday, 2 September 2008
Saturday, 23 August 2008
Download Deemi mp3
 Artist: Deemi: mp3 download Genre(s): Soundtrack Discography:  Soundtracks of my life Year: 2005 Tracks: 20 R&B vocaliser Deemi, hailing from Brooklyn's Bedford-Stuyvesant neighborhood, took gibber severely as early as heights school, attention Manhattan's Talent Unlimited High School. In 1998, she crossed paths with producers Chris Styles and Bruce Waynne. The deuce helped her craft a demo, just she later realized that she should sing more than roughly her possess life story (including physical abuse at the men of her father, as well as organism the mother of deuce children prior to turning 21) than simply interpret common kinship themes. Eventually sign to Atlantic through a partnership 'tween organizations run by Styles and Waynne (the latter is one half of Midi Mafia), Deemi was bell ringer to release her first album, The Soundtrack of My Life, in 2007. |
Download Jenny Owen Youngs
Wednesday, 13 August 2008
Three Researchers To Receive Prestigious Awards From The American Society Of Hematology
�The American Society of
Hematology (ASH), the world's largest professional society of blood
specialists, will honour three scientists who bear made significant
contributions to the savvy of hematologic diseases.
At the 2008 ASH Annual Meeting, Clara D. Bloomfield, M.D., of the Ohio
State University in Columbus, OH, will be presented with the Henry M.
Stratton Medal, intended to honor an individual whose well-recognized
contributions to haematology have taken place over a stop of several
years. Dr. Bloomfield will receive this award for her noteworthy
achievements in the surface area of hematologic malignancies, specially acute
myelogenous leukemia, for more than three decades. Dr Bloomfield has been a
major contributor to the savvy of the biology of these diseases and
the practical use of biologic information in diagnosis, classification, and
determinant prognosis and selection of curative therapeutical approaches.
Kenneth Anderson, M.D., of the Dana-Farber Cancer Institute in Boston,
MA, volition be presented with the William Dameshek Prize, awarded to an
individual world Health Organization has made a late outstanding contribution to the field. Dr.
Anderson will be recognized for his contributions to the treatment of
myeloma. He has advance the field by establishing a new paradigm focussed
not merely on the malignant cell, but too on the microenvironment for the
designation of molecularly-targeted therapies. His rapid translations of
his pre-clinical discoveries into form I-III trials have considerably
improved the clinical final result for myeloma patients.
Robert Kyle, M.D., of the Mayo Clinic in Rochester, MN, will be
presented with the Wallace H. Coulter Award for Lifetime Achievement in
Hematology, which was established in 2007 to honor individuals who receive
made a lifelong committedness to the specialty and whose contributions have
had a major impact on education, research, and/or practice. Dr. Kyle will
receive the laurels for his contributions to the field of study of multiple myeloma,
monoclonal antibody gammopathies, amyloidosis, and related to plasma-cell disorders.
Throughout his 50-year career as a physician-researcher, educator, and
consultant, he has focused on defining these diseases, understanding their
pathogenesis, demonstration, and prognosis, and design and evaluating
therapeutic approaches. In add-on, he has authored more than a thousand
publications has trained more than 200 practicing hematologists.
These awards are named after notable figures in the Society's history
and testament be awarded during the 50th ASH Annual Meeting in December at the
Moscone Center in San Francisco. Dr. Kyle will be presented with his laurels
prior to the Plenary Scientific Session on Sunday, December 7, at 1:30 p.m.
EST. Drs. Bloomfield and Anderson will be presented with their awards at
the Presidential Symposium to be held on Tuesday, December 9, at 9:30 a.m.
For the complete annual meeting schedule and additional information, please
visit hypertext transfer protocol://www.haematology.org/meetings/2008.
The American Society of Hematology is the world's
largest professional
Hematology (ASH), the world's largest professional society of blood
specialists, will honour three scientists who bear made significant
contributions to the savvy of hematologic diseases.
At the 2008 ASH Annual Meeting, Clara D. Bloomfield, M.D., of the Ohio
State University in Columbus, OH, will be presented with the Henry M.
Stratton Medal, intended to honor an individual whose well-recognized
contributions to haematology have taken place over a stop of several
years. Dr. Bloomfield will receive this award for her noteworthy
achievements in the surface area of hematologic malignancies, specially acute
myelogenous leukemia, for more than three decades. Dr Bloomfield has been a
major contributor to the savvy of the biology of these diseases and
the practical use of biologic information in diagnosis, classification, and
determinant prognosis and selection of curative therapeutical approaches.
Kenneth Anderson, M.D., of the Dana-Farber Cancer Institute in Boston,
MA, volition be presented with the William Dameshek Prize, awarded to an
individual world Health Organization has made a late outstanding contribution to the field. Dr.
Anderson will be recognized for his contributions to the treatment of
myeloma. He has advance the field by establishing a new paradigm focussed
not merely on the malignant cell, but too on the microenvironment for the
designation of molecularly-targeted therapies. His rapid translations of
his pre-clinical discoveries into form I-III trials have considerably
improved the clinical final result for myeloma patients.
Robert Kyle, M.D., of the Mayo Clinic in Rochester, MN, will be
presented with the Wallace H. Coulter Award for Lifetime Achievement in
Hematology, which was established in 2007 to honor individuals who receive
made a lifelong committedness to the specialty and whose contributions have
had a major impact on education, research, and/or practice. Dr. Kyle will
receive the laurels for his contributions to the field of study of multiple myeloma,
monoclonal antibody gammopathies, amyloidosis, and related to plasma-cell disorders.
Throughout his 50-year career as a physician-researcher, educator, and
consultant, he has focused on defining these diseases, understanding their
pathogenesis, demonstration, and prognosis, and design and evaluating
therapeutic approaches. In add-on, he has authored more than a thousand
publications has trained more than 200 practicing hematologists.
These awards are named after notable figures in the Society's history
and testament be awarded during the 50th ASH Annual Meeting in December at the
Moscone Center in San Francisco. Dr. Kyle will be presented with his laurels
prior to the Plenary Scientific Session on Sunday, December 7, at 1:30 p.m.
EST. Drs. Bloomfield and Anderson will be presented with their awards at
the Presidential Symposium to be held on Tuesday, December 9, at 9:30 a.m.
For the complete annual meeting schedule and additional information, please
visit hypertext transfer protocol://www.haematology.org/meetings/2008.
The American Society of Hematology is the world's
largest professional
Wednesday, 6 August 2008
Hunger Hormone May Protect Against Stress Induced Depression And Anxiety
�By doing tests on mice federal official on a calorie restricted diet, US researchers take in discovered that ghrelin, a hormone that increases when people
don't eat, may defend against symptoms of depression or anxiety brought on by stress.
The research is the work of scientists lED by aged author Dr Jeffrey Zigman, assistant prof of inner medicine and psychiatry at the University of Texas (UT) Southwestern Medical Center in Dallas. It was published on-line on 15th June
2008 in the journal Nature Neuroscience.
"Our findings in mice suggest that chronic stress causes ghrelin levels to go up and that behaviors associated with depression and anxiety decrease
when ghrelin levels rise," aforesaid Zigman, adding that:
"An unfortunate side result, however, is increased food intake and body weight."
Lead author and instructor of psychiatry at UT Southwestern, Dr Michael Lutter, said:
"Our findings support the idea that these hunger hormones don't do just unitary thing; quite, they align an entire behavioral response to tenseness and
in all probability affect modality, stress and energy levels."
Scientists like Zigman and colleagues already knew that fasting causes the gut to produce ghrelin, which is involved in sending hunger signals to the
mental capacity, and this has lED them to suggest blocking ghrelin as an approach to weight control.
But this new subject shows that if you do that, it could interfere with the body's natural way of dealing with anxiety and natural depression.
For the study, Zigman and his team commit "wild type" (ie not genetically altered in whatever way) mice on a calorie restricted diet for 10 days, which lED to a
four-fold increase in their ghrelin levels. Stress tests involving mazes and forced swims showed that the calorie restricted mice had reduced
symptoms of anxiety and depression compared to control couterparts that had been allowed unrestricted access to food.
The researchers then bred genetically neutered mice whose bodies did not respond to ghrelin and federal official them a calorie restricted diet as well, but under
tenseness tests their depression and anxiety symptoms stayed high; there was no anti-depression or anti-anxiety effect as there had been in the dotty type
mice on the low nutritionist's calorie diet.
Finally, Zigman and colleagues did a third prove, this time to explore social tenseness where normal wild type and genetically altered mice were exposed to aggressive "bully" mice every mean solar day (an access often used to study parallels of depression in humans).
Under stress atmospheric condition both types of mice had raised ghrelin that lasted for up to four weeks after existence bullied for the final time, only the mice that had been genetically altered not to respond to gherlin showed more social shunning behaviour and ate less than the non-altered mice, suggesting they had more depression symptoms.
A possible explanation could be the survival reward that is gained from such an effect over countless generations of evolution where the main
priority is getting enough nutrient to avoid starving to death. Zigman suggested that hunter gatherers needed to remain becalm in order of magnitude to hunt
successfully (or they could end being someone else's meal). Perhaps ghrelin induced by hunger leading to anti-anxiety gave them the edge over
their competitors.
These findings might also explain what happens in conditions like anorexia nervosa aforementioned Lutter:
"We're very interested to see whether ghrelin discourse could help people with anorexia nervosa, with the idea organism that in a certain population,
calorie restriction and weight release could make an antidepressant effect and could be reinforcing for this illness."
Zigman, Lutter and colleagues bob Hope to continue with their research and look at the areas of the brain where ghrelin could be causation these
antidepressant-like effects.
"The orexigenic hormone ghrelin defends against depressive symptoms of continuing stress."
Michael Lutter, Ichiro Sakata, Sherri Osborne-Lawrence, Sherry A Rovinsky, Jason G Anderson, Saendy Jung, Shari Birnbaum, Masashi Yanagisawa,
Joel K Elmquist, Eric J Nestler & Jeffrey M Zigman
Nature Neuroscience Published online 15 June 2008.
DOI: 10.1038/nn.2139
Click here for
Abstract.
Sources: Nature Neuroscience press liberation and abstract.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permit of Medical News Today
More info
don't eat, may defend against symptoms of depression or anxiety brought on by stress.
The research is the work of scientists lED by aged author Dr Jeffrey Zigman, assistant prof of inner medicine and psychiatry at the University of Texas (UT) Southwestern Medical Center in Dallas. It was published on-line on 15th June
2008 in the journal Nature Neuroscience.
"Our findings in mice suggest that chronic stress causes ghrelin levels to go up and that behaviors associated with depression and anxiety decrease
when ghrelin levels rise," aforesaid Zigman, adding that:
"An unfortunate side result, however, is increased food intake and body weight."
Lead author and instructor of psychiatry at UT Southwestern, Dr Michael Lutter, said:
"Our findings support the idea that these hunger hormones don't do just unitary thing; quite, they align an entire behavioral response to tenseness and
in all probability affect modality, stress and energy levels."
Scientists like Zigman and colleagues already knew that fasting causes the gut to produce ghrelin, which is involved in sending hunger signals to the
mental capacity, and this has lED them to suggest blocking ghrelin as an approach to weight control.
But this new subject shows that if you do that, it could interfere with the body's natural way of dealing with anxiety and natural depression.
For the study, Zigman and his team commit "wild type" (ie not genetically altered in whatever way) mice on a calorie restricted diet for 10 days, which lED to a
four-fold increase in their ghrelin levels. Stress tests involving mazes and forced swims showed that the calorie restricted mice had reduced
symptoms of anxiety and depression compared to control couterparts that had been allowed unrestricted access to food.
The researchers then bred genetically neutered mice whose bodies did not respond to ghrelin and federal official them a calorie restricted diet as well, but under
tenseness tests their depression and anxiety symptoms stayed high; there was no anti-depression or anti-anxiety effect as there had been in the dotty type
mice on the low nutritionist's calorie diet.
Finally, Zigman and colleagues did a third prove, this time to explore social tenseness where normal wild type and genetically altered mice were exposed to aggressive "bully" mice every mean solar day (an access often used to study parallels of depression in humans).
Under stress atmospheric condition both types of mice had raised ghrelin that lasted for up to four weeks after existence bullied for the final time, only the mice that had been genetically altered not to respond to gherlin showed more social shunning behaviour and ate less than the non-altered mice, suggesting they had more depression symptoms.
A possible explanation could be the survival reward that is gained from such an effect over countless generations of evolution where the main
priority is getting enough nutrient to avoid starving to death. Zigman suggested that hunter gatherers needed to remain becalm in order of magnitude to hunt
successfully (or they could end being someone else's meal). Perhaps ghrelin induced by hunger leading to anti-anxiety gave them the edge over
their competitors.
These findings might also explain what happens in conditions like anorexia nervosa aforementioned Lutter:
"We're very interested to see whether ghrelin discourse could help people with anorexia nervosa, with the idea organism that in a certain population,
calorie restriction and weight release could make an antidepressant effect and could be reinforcing for this illness."
Zigman, Lutter and colleagues bob Hope to continue with their research and look at the areas of the brain where ghrelin could be causation these
antidepressant-like effects.
"The orexigenic hormone ghrelin defends against depressive symptoms of continuing stress."
Michael Lutter, Ichiro Sakata, Sherri Osborne-Lawrence, Sherry A Rovinsky, Jason G Anderson, Saendy Jung, Shari Birnbaum, Masashi Yanagisawa,
Joel K Elmquist, Eric J Nestler & Jeffrey M Zigman
Nature Neuroscience Published online 15 June 2008.
DOI: 10.1038/nn.2139
Click here for
Abstract.
Sources: Nature Neuroscience press liberation and abstract.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permit of Medical News Today
More info
Friday, 27 June 2008
Gigs around town
EEF BARZELAY
Barzelay, frontman of the Boston-bred, now-disbanded Clem Snide, returns with a new solo album, “Lose Big.” Sunday at T.T. the Bear’s, Cambridge,
617-492-2327.
THE BLACK ANGELS/THE WARLOCKS
With a name stolen from a Velvet Underground tune and an image of one-time Velvet vocalist Nico as its logo, it’s safe to say that Austin’s Black Angels channel a garage-tinted psychedelic sound. The band is touring behind a new CD, “Directions to See a Ghost.” Los Angeles openers the Warlocks are similarly Velvet-obsessed. Sunday at the Middle East, Cambridge, 617-864-EAST.
THE BLACK CROWES
Expect to hear music from “Warpaint,” the new CD by the hard-living, harder-rocking Georgia sextet. Tomorrow and Sunday at Hampton Beach Ballroom Casino, Hampton Beach, New Hampshire, 603-929-4100.
DEVO/TOM TOM CLUB
A little funk and a lot of artsy weirdness, has Devo devolved in 30 years? Talking Heads spin-off the Tom Tom Club supply the rhythmic relief. Tonight at Bank of America Pavilion, 617-728-1600.
RONNIE EARL
Catch local blues guitar star Earl with his Broadcasters supporting their new instrumental live CD, “Hope Radio.” Recorded last year in Acton (a DVD of the show is on the way), the CD got high marks from Guitar Player Magazine. Tomorrow at Regent Theater, Arlington, 781-646-4849.
LYLE LOVETT
Lovett has wrapped up filming his role in“The Open Road,” an upcoming baseball/western flick starring Justin Timberlake. The tall-haired Texan gets back to his musical endeavors with his Large Band. Tonight at South Shore Music Circus, Cohasset, 781-383-9850, and tomorrow at Cape Cod Melody Tent, Hyannis, 508-775-6630.
THE MANHATTANS
The Jersey Citys? No doubt the Garden State r & b harmonizers made the right choice when they decided to name themselves after a place somewhat more storied and romantic than their hometown. Original member Edward Sonny Bivins is still on board, and the Manhattans will no doubt reprise their biggest hits, “Kiss and Say Goodbye” and “Shining Star.” Tonight and tomorrow at Scullers, 617-562-4111.
PETER MURPHY
Barzelay, frontman of the Boston-bred, now-disbanded Clem Snide, returns with a new solo album, “Lose Big.” Sunday at T.T. the Bear’s, Cambridge,
617-492-2327.
THE BLACK ANGELS/THE WARLOCKS
With a name stolen from a Velvet Underground tune and an image of one-time Velvet vocalist Nico as its logo, it’s safe to say that Austin’s Black Angels channel a garage-tinted psychedelic sound. The band is touring behind a new CD, “Directions to See a Ghost.” Los Angeles openers the Warlocks are similarly Velvet-obsessed. Sunday at the Middle East, Cambridge, 617-864-EAST.
THE BLACK CROWES
Expect to hear music from “Warpaint,” the new CD by the hard-living, harder-rocking Georgia sextet. Tomorrow and Sunday at Hampton Beach Ballroom Casino, Hampton Beach, New Hampshire, 603-929-4100.
DEVO/TOM TOM CLUB
A little funk and a lot of artsy weirdness, has Devo devolved in 30 years? Talking Heads spin-off the Tom Tom Club supply the rhythmic relief. Tonight at Bank of America Pavilion, 617-728-1600.
RONNIE EARL
Catch local blues guitar star Earl with his Broadcasters supporting their new instrumental live CD, “Hope Radio.” Recorded last year in Acton (a DVD of the show is on the way), the CD got high marks from Guitar Player Magazine. Tomorrow at Regent Theater, Arlington, 781-646-4849.
LYLE LOVETT
Lovett has wrapped up filming his role in“The Open Road,” an upcoming baseball/western flick starring Justin Timberlake. The tall-haired Texan gets back to his musical endeavors with his Large Band. Tonight at South Shore Music Circus, Cohasset, 781-383-9850, and tomorrow at Cape Cod Melody Tent, Hyannis, 508-775-6630.
THE MANHATTANS
The Jersey Citys? No doubt the Garden State r & b harmonizers made the right choice when they decided to name themselves after a place somewhat more storied and romantic than their hometown. Original member Edward Sonny Bivins is still on board, and the Manhattans will no doubt reprise their biggest hits, “Kiss and Say Goodbye” and “Shining Star.” Tonight and tomorrow at Scullers, 617-562-4111.
PETER MURPHY
Thursday, 19 June 2008
Excruciating Pain
Artist: Excruciating Pain
Genre(s):
Other
Discography:
Thou Shall Choose
Year: 1992
Tracks: 8
J. Holiday
Wednesday, 11 June 2008
McQueen's Widow Urges Swayze To Live It Up
Steve McQueen's widow has urged ailing movie star Patrick Swayze to get the most out of life as he battles pancreatic cancer - because there's no guarantee medication will help. Barbara McQueen insists "miracle cures" won't save Swayze and could make what's left of his life miserable. Now 54, Barbara can still remember her late husband's cancer battle, which ended with his death in 1980 - and she is offering advice to one of her favourite actors as he fights the disease. Barbara tells America's Globe, "It (McQueen's cancer battle) was the worst thing I've ever been through... Tell Patrick not to go there. "It was weird stuff, very unconventional. They tried all kinds of strange things. "Patrick Swayze should kick up his heels with his beloved wife and have fun while he's fighting his desperate battle with cancer." But Swayze insists the treatment he is getting is taking effect and he is "responding well" to it. Swayze confirmed he had been diagnosed with pancreatic cancer at the beginning of 2008.
See Also
See Also
Subscribe to:
Posts (Atom)